Avanafil

Petros Pharmaceuticals shifts strategy to develop a proprietary SaaS and SaMD platform for Rx-to-OTC drug switches, leveraging AI and quantum computing. This aims to expand consumer access to medications, targeting the $38 billion self-care market. The company's technology could facilitate FDA-approved OTC switches, enhancing commercial opportunities.

Petros Pharmaceuticals shifts focus to develop a proprietary SaaS and SaMD platform for Rx-to-OTC switches, aiming to tap into the $38 billion self-care market. Leveraging AI and quantum computing, the technology seeks to facilitate OTC transitions for various drugs, aligning with FDA and HHS policies for expanded medication access.

The article discusses the intimate lives of older people, emphasizing that age does not limit sexual activity. It highlights potential challenges like erectile dysfunction and decreased libido but also the benefits of maintaining an active intimate life, including improved health and social life. Tips for seniors include regular health check-ups, maintaining an active lifestyle, considering ED medication, and practicing safe sex. The article also touches on the importance of communication with partners and adapting to changes together.

Petros Pharmaceuticals integrates AI into a Human Factors Study for STENDRA (avanafil), aiming for OTC status. The AI tool, developed with a software developer, assesses safe drug administration. The study, following FDA guidance, evaluates the web app's effectiveness for patient self-screening, supporting STENDRA's potential as the first OTC erectile dysfunction medication.

Petros Pharmaceuticals launched an AI tool in collaboration with a major software provider, integrating it into a web app for patient self-screening. This tool aims to optimize STENDRA's OTC availability, addressing FDA requests for safe drug administration. A Human Factors Study assesses the web app's safety and effectiveness, supporting Petros' goal to make STENDRA the first OTC erectile dysfunction medication.

Petros Pharmaceuticals partners with an AI software provider to facilitate STENDRA's transition to over-the-counter status, aiming to enhance self-screening for erectile dysfunction treatment. This initiative aligns with FDA and ACNU guidelines, leveraging AI for safe, appropriate consumer access.